Liraglutide (Victoza) found to be effective for chronic weight management in non-diabetic obese patients


A new study published in the New England Journal of Medicine demonstrated that 3.0 mg of liraglutide daily over 56 weeks along with monthly lifestyle counseling lead to a sustained average weight loss of 8.4 kg.

There was noted improvement in some secondary end points including glycemic control, cardiometabolic markers, quality of life, and progression to diabetes.

There was no evidence of increases in thyroid cancer over the length of the study.

I do believe that this drug may prove useful in obese and overweight patients who are at high risk of developing diabetes (aka pt with impaired glucose tolerance or impaired fasting glucose). Keeping in mind of course the price of the drug and the fact that it needs to be injected which may affect compliance.

Here is a link to the article and editorial.

Posted by Dr. Dimitre on 08/07/2015